Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-07 am EDT			5-day change	1st Jan Change
441.20 ^DKK	-2.24%		+0.85%	-29.32%

Jul. 07	Italy set to speed through $2.3 billion Novo Nordisk investment	RE
Jul. 07	Italy set to speed through $2.3 billion Novo Nordisk investment	RE

NOVO NORDISK : Acknowledging the intensifying competition

Published on 06/06/2025 at 11:40

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
The importance of being constantly changing…	Jul. 07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	Jul. 04	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	Jul. 03	RE
NOVO NORDISK : UBS reiterates its Buy rating	Jul. 03	ZD
Ascletis Pharma Begins Dosing Subjects in US Weight Management Drug Study; Shares Gain 3%	Jul. 02	MT
How did Novo Nordisk lose the US market?	Jul. 02
Novo Nordisk, WeightWatchers Expand Collaboration for Enhanced Access to Wegovy	Jul. 01	MT
WW International, Inc. and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care	Jul. 01	CI
How Novo Nordisk misread the US market for its weight loss sensation	Jul. 01	RE
How Novo Nordisk misread the US market for its weight loss sensation	Jul. 01	RE
Sector Update: Health Care Stocks Advance Tuesday Afternoon	Jul. 01	MT
European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises to 2%	Jul. 01	MT
Top Midday Stories: Powell Blames Tariffs for Rate Pause; Tesla Shares Fall on Trump-Musk Feud	Jul. 01	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	Jul. 01	MT
China's Innogen expects to complete weight-loss drug trials next year	Jul. 01	RE
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Jul. 01	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	Jul. 01	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	Jul. 01	MT
NOVO NORDISK : Receives a Buy rating from UBS	Jul. 01	ZD
Goldman Sachs Lowers Novo Nordisk Price Target to 745 Danish Kroner (from 775), Reiterates Buy - BN	Jul. 01	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

Aug. 06 - Q2 2025 Earnings Release

More about the company